

Iktos, Teijin Pharma to co-develop new technology for small molecule drug discovery

06 April 2022 | News

Applying artificial Intelligence for new drug design



French firm Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Japan's Teijin Pharma Limited, the core company of the Teijin Group's healthcare business that provides comprehensive healthcare services to improve the quality of life, have announced a strategic collaboration agreement in Artificial Intelligence for new drug design.

Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharma's small molecule drug discovery projects to expedite the identification of potential pre-clinical candidates. Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process, leveraging Iktos' proprietary know-how in AI for Computer Aided Drug Design (CADD) and complementing Teijin's research and development capabilities.

Based on the recent drastic demographic change and increased health consciousness, Teijin Pharma is committed to providing healthcare solutions in the priority fields of bone, joint, rehabilitation, neurology, respiratory, cardiovascular and metabolic diseases. Creating innovative drugs is one of the company's core business strategies and Teijin Pharma is now focusing on strengthening technological foundation for small molecule drugs that play major roles among the drug modalities for innovative drug discovery.